^
    Back
    Association details:
    Biomarker:AR mutation
    Cancer:Prostate Cancer
    Drug:abiraterone acetate (CYP17A1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASCO 2020
    Title:

    AR enhancer and locus genomic alterations as cell-free DNA biomarkers of primary resistance to AR-directed treatment of metastatic prostate cancer.

    Published date:
    05/13/2020
    Excerpt:
    AR/enhancer alterations (copy gain, tandem duplication, and point mutation) in cfDNA were strongly predictive of primary resistance to AR-directed therapy (PPV = 100%, Sens. = 89%).
    DOI:
    10.1200/JCO.2020.38.15_suppl.5529